Phase 1 Study With Sorafenib and Sirolimus

Inclusion Criteria: * Patients with histological or cytological confirmed advanced solid tumor, which is refractory to standard therapies or for which no standard therapy exists and for which there is a rationale for the therapeutic use of a combination of sorafenib and sirolimus (especially metastic RCC, malignant melanoma, HCC, NSCLC, pancreatic cancer, hormone refractory prostate cancer). * Men or women of at least 18 years * Patients who have an ECOG status of 0 or 1 * Patients who have a life expectancy of at least 12 weeks * Adequate bone marrow, liver and renal function * Negative pregnancy test for female patients of childbearing potential * Women and men enrolled into this trial must use adequate birth control measures during the course of the trial. * Signed informed consent Exclusion Criteria: * History of serious cardiac disease * Active clinically serious bacterial, viral or fungal infections (\> grade 2). * Known history of human immunodeficiency virus (HIV) infection or chronic hepatitis B or C. * Clinically symptomatic brain or meningeal metastasis. * Patients with seizure disorders requiring medication (such as steroids or antiepileptics). * Patients with evidence or history of bleeding diathesis. * Substance abuse, medical, psychological or social conditions that may interfere with the patients participation in the study or evaluation of the study results. * Concomitant treatment with strong CYP3A4 inductors (such as rifampicin, St. John´s Wort) or CYP3A4 inhibitors (such as ketoconazole, voriconazole, itraconazole, diltiazem, verapamil, erythromycin). Moderate or weak CYP3A4 modifiers should be used concomitantly only after careful assessment of risk-benefit ratio. Concomitant use of carbamazepine, phenobarbital, phenytoin or chronic use of dexamethasone is excluded